The quote below is from page 20 of the IPIX Corporate Overview dated June 2020:
“Brilacidin is 1 of only 7 “qualifying” antibiotics* in development DRIVE AB** says would merit a proposed Market Entry Reward ($1bn) due to its ability to kill “critical” or “high priority” pathogens.”
https://static1.squarespace.com/static/571535...+2020+.pdf
http://drive-ab.eu/wp-content/uploads/2018/01...an2018.pdf
“Brilacidin is 1 of only 7 “qualifying” antibiotics* in development DRIVE AB** says would merit a proposed Market Entry Reward ($1bn) due to its ability to kill “critical” or “high priority” pathogens.”
https://static1.squarespace.com/static/571535...+2020+.pdf
http://drive-ab.eu/wp-content/uploads/2018/01...an2018.pdf
9
1